1416358-33-2

Upstream product

• 1416358-09-2 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-4-(3-nitrophenyl)-1H-1,2,4-triazol-5(4H)-one 
• 86386-77-8 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazole methanesulfonate 
• 86404-63-9 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazolyl)ethanone 
• 20651-71-2 4-butyl benzoic acid 
• 1416358-11-6 4-(3-aminophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one 
• 51336-94-8 2-chloro-1-(2,4-dichlorophenyl)ethanone 
• 372-18-9 1,3-Difluorobenzene 
• 86386-76-7 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazole 
• 1416358-04-7 4-(3-nitrophenyl)-1H-1,2,4-triazol-5(4H)-one 
• 99-09-2 3-nitro-aniline 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel 1, 2, 4-triazole derivatives as antifungal agent

A series of novel 1, 2, 4-triazole derivatives (9a-p) have been designed and synthesized as the potential antifungal agents. All compounds were characterized by 1H-NMR, 13C-NMR, and LCMS. Their antifungal activities against seven human pathogenic fungi were evaluated in vitro by measuring the minimal inhibitory concentrations. Most of the tested compounds were found to be more potent against Candida albicans than the control drug fluconazole.